Leaders of the anti-vaccine movement and anti-vaccine groups have seized upon the suspension of the Oxford/AstraZeneca vaccine as evidence all COVID-19 vaccines are inherently unsafe. During the week of 3/8 – 3/15, the rollout of the Oxford/AstraZeneca vaccine had been suspended in various European countries over fears of blood clots. Most countries suspended the vaccine out of an abundance of caution while they investigated a handful of cases. AstraZeneca stated that they observed no increased risk of pulmonary embolism or deep vein thrombosis in clinical trials, and that the number of events is lower among those who have received the vaccine, compared to what would be expected under normal circumstances among the general population. As of 3/19, the European drug regulator has recommended vaccinations resume. Countries are making independent determinations. Researchers are studying what role the vaccine could have played in the events, with some early results (see links), and prevention and treatment options.
Recommendation:
Passive Response Read More +
While communications directly to the public regarding ongoing Oxford/AstraZeneca policy changes and research may distract from higher priority talking points, updating informational materials regarding the Oxford/AstraZeneca vaccine is recommended as European health authorities are updating the public regarding decisions about safety and policies. White House Chief Medical Officer Dr. Anthony Fauci has stated that he expects the vaccine will receive authorization in the U.S. in April. In preparation for this expected approval, communications staff should be familiar with official announcements regarding the vaccine made in Europe and elsewhere. Fact Checking Source(s):wsj.com, politico.eu
Sign Up for Public Health Alerts
About Us
Learn More